Frequent mitotic activity in banal melanocytic nevi uncovered by immunohistochemical analysis

American Journal of Dermatopathology

Volumn 32, Issue 7, 2010, Pages 643-649

  Glatz, Katharina ^a   Hartmann, Christoph ^a   Antic, Milos ^a   Kutzner, Heinz ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Dermatopathologie Bodensee   (Germany)

Author keywords

immunohistochemistry; mitotic activity; nevus

Indexed keywords

EOSIN; HEMATOXYLIN; HISTONE H3; MARKER; PHOSPHO HISTONE H3 SERINE 28; SERINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DERMIS; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; JUVENILE MELANOMA; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MITOSIS RATE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN SURFACE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MELANOMA; MIDDLE AGED; MITOSIS; NEVUS, PIGMENTED; SKIN NEOPLASMS; YOUNG ADULT;

EID: 77957374841     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181d7ce6f     Document Type: Article

References (19)

1. McKee PH, Calonje E. Diagnostic Atlas of Melanocytic Pathology. Oxford: Elsevier; 2009.
2. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and surviving immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol. 2008;30:117-122.
3. Jensen SL, Radfar A, Bhawan J. Mitoses in conventional melanocytic nevi. J Cutan Pathol. 2007;34:713-715.
4. Bergman R, Malkin L, Sabo E, et al. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol. 2001;44:500-504.
5. Kanter L, Blegen H, Wejde J, et al. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties. Melanoma Res. 1995;5: 345-350.
6. Smolle J, Soyer HP, Kerl H. Proliferative activity of cutaneous melanocytic tumors defined by Ki-67 monoclonal antibody. A quantitative immunohistochemical study. Am J Dermatopathol. 1989;11:301-307.
7. Stefanaki C, Stefanaki K, Antoniou C, et al. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas. J Cutan Pathol. 2008;35:799-808.
8. Tapia C, Kutzner H, Mentzel T, et al. Two mitosis-specific antibodies, MPM-2 and phospho-histone H3 (Ser28), allow rapid and precise determination of mitotic activity. Am J Surg Pathol. 2006;30:83-89.
9. Barnhill RL, Piepkorn M, Busam KJ. Pathology of Melanocytic Nevi and Malignant Melanoma. New York: Springer Verlag; 2004.
10. Massi G, LeBoit PE. Histological Diagnosis of Nevi and Melanoma. Darmstadt: Steinkopff Verlag; 2004.
11. Attis MG, Vollmer RT. Mitotic rate in melanoma: a reexamination. Am J Clin Pathol. 2007;127:380-384.
12. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498.
13. Lund HZ, Stobbe GD. The natural history of the pigmented nevus; factors of age and anatomic location. Am J Pathol. 1949;25:1117-1155, incl 1114 pl.
14. Stegmaier OC Jr, Montgomery H. Histopathologic studies of pigmented nevi in children. J Invest Dermatol. 1953;20:51-64.
15. Culpepper KS, Granter SR, McKee PH. My approach to atypical melanocytic lesions. J Clin Pathol. 2004;57:1121-1131.
16. Strungs I. Common and uncommon variants of melanocytic naevi. Pathology. 2004;36:396-403.
17. Tronnier M, Rudolph P, Koser T, et al. One single erythemagenic UV irradiation is more effective in increasing the proliferative activity of melanocytes in melanocytic naevi compared with fractionally applied high doses. Br J Dermatol. 1997;137:534-539.
18. Okun MR, Edelstein LM, Kasznica J, et al. What criteria reliably distinguish melanoma from benign melanocytic lesions? Histopathology. 2000;37:464-472.
19. Rudolph P, Lappe T, Schubert C, et al. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol. 1995;147:1615-1625.